The Life Sciences M + A team advised AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) on the mutual termination with Palatin Technologies, Inc. of the January 2017 license agreement pursuant to which AMAG was granted exclusive rights to develop and commercialize Vyleesi® (bremelanotide), a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, in North America. Under the terms of the termination agreement, all of AMAG’s rights and obligations to develop and commercialize Vyleesi under the license agreement will terminate, and full ownership of Vyleesi will transfer back to Palatin. AMAG has agreed to provide certain transitional services to Palatin for a limited transition period to ensure continued patient access to Vyleesi®. Together with the sale of its rights to Intrarosa® to Millicent Pharma, on which Goodwin also advised AMAG, this transaction marks the completion of AMAG’s divestment of its women’s health assets.
AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas. Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
AMAG, Goodwin’s long-time public company client led by Stuart Cable and Jacqueline Mercier, was supported on this deal by an interdisciplinary deal team led by Robert Crawford and Mayan Katz.
For more details, please read the press release.